Effect of Current Antibody-Mediated Rejection (AMR) Treatments on Microvascular Inflammation (MVI) in Kidney Transplant Recipients: A Rapid Literature Review (RLR) and Meta-Analysis (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1179; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "The RLR was limited to studies evaluating combinations of apheresis (plasmapheresis or immunoadsorption), intravenous immunoglobulin (IVIG), and steroids, with or without rituximab...Conclusion Current treatments for AMR are associated with small, and unlikely clinically meaningful, reductions in MVI scores at 6 months. These data provide a benchmark for MVI response with commonly used treatments, underscoring the need for therapies that more effectively address microvascular injury to the graft."
Retrospective data • Review • Antibody-mediated Rejection • Inflammation • Transplantation
|
|
Alexander C. Wiseman; Matthias Diebold; Samir Patel; Brandon Butcher; Laura Stong; Connie Ly; Vikas Jangra; Mingxin Liu; Cristiana Tzonev; Jose Salvador Marcano Belisario; Paolo Cravedi
|